[go: up one dir, main page]

FI63741C - Analogifoerfarande foer framstaellning av nya substituerade feoxipropanolaminer med hjaertselektiv beta-receptor blocke rade verkan - Google Patents

Analogifoerfarande foer framstaellning av nya substituerade feoxipropanolaminer med hjaertselektiv beta-receptor blocke rade verkan Download PDF

Info

Publication number
FI63741C
FI63741C FI1026/73A FI102673A FI63741C FI 63741 C FI63741 C FI 63741C FI 1026/73 A FI1026/73 A FI 1026/73A FI 102673 A FI102673 A FI 102673A FI 63741 C FI63741 C FI 63741C
Authority
FI
Finland
Prior art keywords
phenoxy
isopropylamino
formula
propanol
residue
Prior art date
Application number
FI1026/73A
Other languages
English (en)
Finnish (fi)
Other versions
FI63741B (fi
Inventor
Peder Bernhard Berntsson
Arne Elof Braendstroem
Enar Ingemar Carlsson
Stig Aoke Ingemar Carlsson
Lars Ek
Benny Roger Samuelsson
Sven Erik Sjoestrand
Gert Christer Strandlund
Bengt Arne Hjalmar Aoblad
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haessle Ab filed Critical Haessle Ab
Application granted granted Critical
Publication of FI63741B publication Critical patent/FI63741B/fi
Publication of FI63741C publication Critical patent/FI63741C/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)

Claims (3)

1. Analogiamenetelmä uusien substituoitujen fenoksipropanoli— amiinien sekä näiden farmaseuttisesti hyväksyttävien suolojen valmistamiseksi , joilla on sydänselektiivinen $—reseptoria estävä vaikutus, ja joilla on kaava I r2—- o-ch2chohch2-nh-r1 (I) jossa kaavassa R^ on alempi alkyyli, R2 on alempialkoksialempial-kyyli, alempialkyylitioalempialkyyli, alempialkoksikarbonyyliamino-alempialkyyli tai alempialkoksialempialkoksi, ja R^ on halogeeni, alempi alkyyli, alempi alkenyyli, alempi alkoksimetyyli tai alempi alkoksi, tunnettu siitä, että a) yhdiste, jolla on kaava II X1 r2—(f y-o-ch2-ch-ch2-z (ii) N. R3 jossa R2 ja tarkoittavat samaa kuin edellä, X^ on hydroksyyli-ryhmä ja Z on reaktiokykyinen esteröity hydroksyyliryhmä, tai ja Z muodostavat yhdessä epoksiryhmän, saatetaan reagoimaan sellaisen amiinin kanssa, jolla on kaava NH2~R^, jossa tarkoittaa samaa kuin edellä, tai b) yhdiste, jolla on kaava III R2- v—^- 0-OH2CHOHCH2-NH2 (III) R3 jossa R2 ja R^ tarkoittavat samaa kuin edellä, saatetaan reagoimaan sellaisen yhdisteen kanssa, jolla on kaava Z-R^ jossa Z ja R^ tarkoittavat samaa kuin edellä, tai 63741 57 c) yhdiste, jolla on kaava IV f.2—(( y-oh (iv) R3 jossa R2 ja R^ tarkoittavat samaa kuin edellä, saatetaan reagoimaan yhdisteen kanssa, jolla on kaava V ΐ1 Z-CH2-CH-CH2-NH-R1 (V) jossa kaavassa Z, X^ ja R^ tarkoittavat samaa kuin edellä, tai d) kaavan VI mukaisesta yhdisteestä ix r2—( y-och2chohch2-n-r1 (vi) R3 jossa R^, R2 ja R^ merkitsevät samaa kuin yllä ja Rx on lohkais-tava suojaryhmä, lohkaistaan suojaryhmä R , tai Λ e) pelkistetään kaavan VII tai VIII mukainen Schiff’in emäs OH R2 -(f )- OCH2-CH-CH = N-R1 (VII) - R3 OH R2—(/ )- 0-CH2-CH-CH2-N=R1, (VIII) N tai kaavaa VIII vastaava rengastautomeeri, jolla on kaava IX r2-<Q>-- o-ch2-ch-0H2 (IX) R, 0 NH J p S Ri· 58 63741 jossa kaavassa R^, R2 ja R^ tarkoittavat samaa kuin edellä ja R-pH on sama kuin R^ ja jolloin kaavojen VIII ja IX mukaiset yhdisteet voivat esiintyä samanaikaisesti, tai f) kaavan XI mukaisessa yhdisteessä /-\ °H Xj—(f S-O-CHj-CH-CHj-NH-R^^ (XI) R3 jossa kaavassa R^ ja R^ tarkoittavat samaa kuin edellä ja X2 on jäännökseksi R2, joka tarkoittaa samaa kuin yllä, muutettavissa oleva jäännös, tämä jäännös X2 valitaan ryhmästä, joka koostuu I) Z^-alemmasta alkyylistä, II) Z-alemmasta alkyylistä, III) Z-^-alemmasta alkoksista ja IV) OH, jossa Z ja Z^ ovat hydroksi tai merkapto toisen ollessa halogeeni tai epäorgaanisen hapon jäännös joka kun X2 on I) saatetaan reagoimaan metyyli-Z2:n, etyyli-Z2:n, isopro-pyyli-Z2:n tai n-propyyli-Z2:n kanssa, jossa Z^ on hydroksi tai merkapto kun Z^ on Z tai Z2 on halogeeni tai epäorgaanisen hapon jäännös kun Z^ on hydroksi tai merkapto; X2 on II) saatetaan reagoimaan metoksikarbonyyliamiinin tai etoksi-karbonyyliamiinin kanssa; X2 on III) saatetaan reagoimaan metyyli-Z2:n tai etyyli-Z2:n kanssa, jossa Z2 on hydroksi kun Z^ on Z, joka tarkoittaa samaa kuin edellä tai Z2 on Z, joka tarkoittaa samaa kuin edellä kun Z^ on hydroksi; tai X2 on IV) saatetaan reagoimaan metoksimetyyli-Z:n, etoksimetyyli-Z:n, 2- metoksietyyli-Z:n, 1-metoksietyyli-Z:n, 4-metoksi-n-butyyli-Z:n, 3- metoksi-n-butyylin tai 3-metoksi-n-propyylin kanssa, jossa Z:lla on yllä mainittu merkitys g) kaavan XVIII mukaisessa yhdisteessä /-\ °H ° R2—$ \-O-CH^iJh-C-NH-Rj (XVIII) ^R3 II 59 63741 pelkistetään alkanolisivuketjussa oleva karbonyyliryhmä mety-leeniryhmäksi.
2. Patenttivaatimuksen 1 mukainen menetelmä, tunnettu siitä, että saattamalla isopropyyliamiini ja tert.-butyyli-amiini sekä l,2-epoksi-2,4-disubstituoitu fenoksipropaani reagoimaan, valmistetaan: 1. l-/2-bromi-4-(2-metoksietyyli)-fenoksi7-2-hydroksi-3- isopropyyliamino-propaani, 2. l-/2-kloori-4- ( 2-metoksietyyli ) f enoksi?-2-hydroksi-3~ isopropyyliamino-propaani, 3. l-/2-kloori-4-(2-metoksietyyli)-fenoksi7-2-hydroksi-3-tert-butyyliamino-propaani, 4. l-/2-bromi-4-(2-metoksietoksi)-fenoksi?-2-hydroksi-3_ isopropyyliamino-propaani, 5. l-/2-metoksimetyyli-4-(2-metoksietyyli)-fenoksi7-2-hydroksi-3-isopropyyliamino-propaani, 6. l-/2-allyyli-4-(2-metoksietoksi)-fenoksi7-2-hydroksi- 3-isopropyyliamino-propaani, 7. l-/2-metoksi-4-(2-metoksikarbonyyliaminoetyyli)-fenoksi7- 2-hydroksi-3-isopropyyliamino-propaani, tai 8. l-/2-kloori-4-(2-metoksikarbonyyli-aminoetyyli)-fenoksi7- 2-hydroksi-3-isopropyyliamino-propaani.
1. Analogiförfarande för framställning av nya substituerade fenoxipropanolaminer samt farmaceutiskt acceptabla salter därav med hjärtselektiv β-receptorblockerande verkan enligt formel I r2—y--o-ch2chohch2-nh-r1 (I) där R1 är lägre alkyl, R2 är lägrealkoxilägrealkyl, lägrealkyltio-lägrealkyl, lägrealkoxikarbonylaminolägrealkyl eller lägrealkoxi-lägrealkoxi 0ch är halogen, lägre alkyl, lägre alkenyl, lägre alkoximetyl eller lägre alkoxi, kännetecknat därav, att man omsätter a) en förening enligt formel II 60 63741 Xl R2 \ /--0-CH2-CH-CH2-Z (II) R3 där R2 och har samma betydelse som ovan, X^ stär för en hydroxyl-grupp och Z star för en reaktiv, förestrad hydroxylgrupp, eller och Z bildar tillsammans en epoxigrupp, med en amin en-ligt formel NH2~R^, där R^ har samma betydelse som ovan eller b) en förening enligt formel III r2—V-^- 0-0H2CH0HCH2-NH2 (III) R3 där R2 och R^ har samma betydelse som ovan, med en förening enligt formel Z-R^, där Z och R^ har samma betydelse som ovan eller c) en förening enligt formeln IV R2-Q-- OH (IV) R3 där R2 och har samma betydelse som ovan med en förening enligt formel V f1 Z-CH2-CH-CH2-NH-R1 (V) där Z, X^ och R^ har samma betydelse som ovan, eller d) i en förening med formeln vi Rx R2 -V_^- OCHjCHOHCHj-N-Rj^ (VI) R3 vari R^, R2 och R^ har ovan angiven betydelse och Rx är en avspalt-bar skyddsgrupp, Rx avspaltas, eller II 61 63741 e) en Schiff's bas enligt formel VII eller VIII OH r2—y--och2-ch-ch=n-r1 (vii) \\ R3 OH r2—-0-CH2-CH-CH2-N=R1 , (VIII) R3 eller formel VIII motsvarande ring-tautomer enligt formel IX r2—^--o-ch2-ch-ch2 (IX) R, 0 NH 3 / Kl' där R^, R2 och R^ har samma betydelse som ovan och R-^,Η är samma som R-^ och varvid föreningarna enligt formlerna VIII och IX kan föreligga samtidigt, reduceras, eller f) i en förening enligt formel XI OH X2 —-0-CH2-CH-CH2-NH-R1 (XI) R3 där och R^ har samma betydelse som ovan och där X2 är en tili en rest R2, som har ovan angiven betydelse, överförbar rest vald ur den grupp som bestär av I) Z^-lägre alkyl, II) Z-lägre alkyl, III) Z^lägre alkoxi och IV) OH väri Z och Z^ är hydroxi eller merkapto och den andra är halogen eller en rest av en oorganisk syra som da X2 är I) omsättes med metyl-Z2, etyl-Z2, isopropyl-Z2 eller n-propyl-Z2, väri Z2 är hydroxi eller merkapto dä är Z eller Z2 är halogen eller en rest av en oorganisk syra dä Z^ är hydroxi eller merkapto;
FI1026/73A 1972-04-04 1973-04-03 Analogifoerfarande foer framstaellning av nya substituerade feoxipropanolaminer med hjaertselektiv beta-receptor blocke rade verkan FI63741C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE7204321A SE384853B (sv) 1972-04-04 1972-04-04 Forfarande for framstellning av nya aminer
SE432172 1972-04-04

Publications (2)

Publication Number Publication Date
FI63741B FI63741B (fi) 1983-04-29
FI63741C true FI63741C (fi) 1983-08-10

Family

ID=20263926

Family Applications (1)

Application Number Title Priority Date Filing Date
FI1026/73A FI63741C (fi) 1972-04-04 1973-04-03 Analogifoerfarande foer framstaellning av nya substituerade feoxipropanolaminer med hjaertselektiv beta-receptor blocke rade verkan

Country Status (19)

Country Link
US (1) US3996382A (sv)
JP (1) JPS5924971B2 (sv)
AR (1) AR204982A1 (sv)
AT (1) AT321276B (sv)
BE (1) BE797414A (sv)
BR (1) BR7302430D0 (sv)
CA (1) CA1017755A (sv)
CH (3) CH587224A5 (sv)
DE (1) DE2316727C3 (sv)
ES (3) ES413316A1 (sv)
FI (1) FI63741C (sv)
FR (1) FR2179069B1 (sv)
GB (1) GB1421824A (sv)
IE (1) IE38302B1 (sv)
NL (1) NL7304606A (sv)
NO (1) NO139167C (sv)
SE (1) SE384853B (sv)
SU (1) SU533336A3 (sv)
ZA (1) ZA732119B (sv)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU169464B (sv) * 1974-02-20 1976-11-28
IL48309A (en) * 1974-10-25 1980-01-31 Robins Co Inc A H 1-aryloxy-4-amino-2-butanols and pharmaceutical compositions containing them
JPS5337126A (en) * 1976-09-17 1978-04-06 Nishida Marine Boiler Obtaining method of nickel from low grade nickel ore
JPS55161036A (en) * 1979-06-05 1980-12-15 Ooeyama Nickel Kk Nickel oxide ore smelting method
ZW9881A1 (en) * 1980-06-02 1981-12-23 Hoffmann La Roche Substituted phenoxyaminopropanol derivatives
FR2497194B1 (fr) * 1980-08-07 1985-06-14 Sandoz Sa Nouveaux composes phenoliques
CH643527A5 (en) * 1980-10-24 1984-06-15 Ciba Geigy Ag Process for the preparation of 1-alkylamino-3-(4-(2-lower alkoxy-ethyl)phenoxy)-2-propanols
DE3125636A1 (de) * 1981-06-30 1983-01-13 Merck Patent Gmbh, 6100 Darmstadt 1-(p-2-isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur senkung des augeninnendrucks und ophtalmikum, enthalten diese verbindung
SE457505B (sv) * 1984-01-10 1989-01-09 Lejus Medical Ab Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning
US5064827A (en) * 1988-12-15 1991-11-12 Du Pont Merck Pharmaceutical Company Polyhydroxybenzyloxpropanolamines
US4959390A (en) * 1988-12-15 1990-09-25 E. I. Du Pont De Nemours And Company Polyhydroxybenzyloxypropanolamines
KR100489649B1 (ko) * 1998-04-14 2005-09-02 삼성정밀화학 주식회사 (s)-3-치환-2-히드록시프로필아민의제조방법
KR100469946B1 (ko) * 1998-04-14 2005-05-17 삼성정밀화학 주식회사 키랄(s)-2,3-치환-1-프로필아민유도체의제조방법
KR100469947B1 (ko) * 1998-04-14 2005-04-08 삼성정밀화학 주식회사 키랄(s)-3-아미노-1,2-프로판디올의제조방법
US20010018446A1 (en) 1999-09-23 2001-08-30 G.D. Searle & Co. Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1220440B (de) * 1962-02-14 1966-07-07 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen
US3459782A (en) * 1963-08-26 1969-08-05 Boehringer Sohn Ingelheim 1-substituted phenoxy-2-hydroxy-3-isopropylamino-propanes
CH465640A (de) * 1964-09-10 1968-11-30 Ciba Geigy Verfahren zur Herstellung neuer Amine
NL6504268A (sv) * 1965-04-03 1966-10-04
FR1547605A (fr) * 1967-09-27 1968-11-29 Amp Inc Connecteurs pour fusibles en cartouches
SE358382B (sv) * 1967-12-18 1973-07-30 Boehringer Sohn Ingelheim
US3740444A (en) * 1968-01-25 1973-06-19 Boehringer Sohn Ingelheim Therapeutic compositions and method
GB1285038A (en) * 1969-02-21 1972-08-09 Ici Ltd Alkanolamine derivatives
US3639634A (en) * 1969-03-06 1972-02-01 Dow Chemical Co Cardiac antiarrhythmic method and composition employing alkylamino-alkoxyhalophenol compounds
JPS4943947B1 (sv) * 1970-04-03 1974-11-25
SE372762B (sv) * 1969-05-21 1975-01-13 Haessle Ab
SE354851B (sv) * 1970-02-18 1973-03-26 Haessle Ab
JPS5146113B2 (sv) * 1972-09-01 1976-12-07

Also Published As

Publication number Publication date
CH587222A5 (sv) 1977-04-29
GB1421824A (en) 1976-01-21
DE2316727B2 (de) 1978-06-22
DE2316727A1 (de) 1974-01-10
AR204982A1 (es) 1976-03-31
ES439804A1 (es) 1977-04-16
IE38302L (en) 1973-10-04
FR2179069A1 (sv) 1973-11-16
BE797414A (fr) 1973-07-16
AT321276B (de) 1975-03-25
NO139167C (no) 1979-01-17
CH587225A5 (sv) 1977-04-29
DE2316727C3 (de) 1979-02-22
CA1017755A (en) 1977-09-20
ZA732119B (en) 1974-01-30
ES413316A1 (es) 1976-06-01
BR7302430D0 (pt) 1974-02-07
IE38302B1 (en) 1978-02-15
ES439803A1 (es) 1977-04-16
SU533336A3 (ru) 1976-10-25
SE384853B (sv) 1976-05-24
NL7304606A (sv) 1973-10-08
US3996382A (en) 1976-12-07
NO139167B (no) 1978-10-09
JPS5924971B2 (ja) 1984-06-13
CH587224A5 (sv) 1977-04-29
FI63741B (fi) 1983-04-29
JPS4913129A (sv) 1974-02-05
FR2179069B1 (sv) 1976-04-09

Similar Documents

Publication Publication Date Title
FI63741C (fi) Analogifoerfarande foer framstaellning av nya substituerade feoxipropanolaminer med hjaertselektiv beta-receptor blocke rade verkan
AU706752B2 (en) Inhibitors of influenza virus neuraminidase and methods of making and using the same
EP0011609B1 (en) Xanthine derivatives and pharmaceutical preparations containing these derivatives for use in the treatment of chronic obstructive airway disease and cardiac disease
EP2123271A1 (en) Drug for treatment of influenza
FI63745B (fi) Foerfarande foer framstaellning av nya terapeutiskt vaerdefulla aminer
US10786476B2 (en) Combination therapy
JPS6146453B2 (sv)
EP2725018A1 (en) Substituted cinnamamide derivative, preparation method and use thereof
NO140628B (no) Analogifremgangsmaate for fremstilling av nye, terapeutisk virksomme aminer
JP6952911B2 (ja) 2−(αヒドロキシペンチル)安息香酸の有機アミンエステル誘導体薬物
Tullar et al. Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects
NO792113L (no) Membranstabiliserende forbindelser som har beta-receptor blokkerende aktivitet, deres fremgangsmaate samt fremgangsmaate for behandling av arrhytmetiske tilstander, og farmasoeytiske preparater som inneholder disse
NO144773B (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive aminer
CS239948B2 (en) Processing of substitute n-carboxamidealkylfenoxypropanolamine
JPS6213952B2 (sv)
WO2008108842A1 (en) Lisofylline analogs and methods for use
US4145442A (en) Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases
EP4310070A1 (en) Use of trans amantadine derivative or salt thereof
HU177638B (en) Process for producing 3-bracket-2-phenoxy-ethyl-amino-bracket-1-phenoxy-propanoles
CA1167869A (en) Antiviral 1,2,3,4-tetrahydro-1,4-methanonaphthalene derivatives
US4035420A (en) Substituted ureido alkylene phenoxy propanolamines
US20100105690A1 (en) Lisofylline analogs and methods for use
JP2560083B2 (ja) 心血管系の治療において活性な化合物
JP2021505573A (ja) ベータ−2選択的アドレナリン性受容体アゴニスト
GB2068963A (en) Basic ethers of 4-hydroxy-benzophenones acting as beta-blocking agents and relevant preparation processes